MindWalk (NASDAQ:HYFT) Trading Up 5.8% – Here’s What Happened

MindWalk Holdings Corp. (NASDAQ:HYFT)’s share price shot up 5.8% during trading on Friday . The company traded as high as $1.29 and last traded at $1.27. 244,976 shares traded hands during trading, an increase of 45% from the average session volume of 168,838 shares. The stock had previously closed at $1.20.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HYFT. Zacks Research upgraded MindWalk from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. HC Wainwright reiterated a “buy” rating on shares of MindWalk in a report on Friday, March 13th. Weiss Ratings started coverage on MindWalk in a report on Wednesday, January 14th. They set a “sell (d-)” rating on the stock. UBS Group restated a “buy” rating on shares of MindWalk in a research note on Friday, March 13th. Finally, JonesTrading started coverage on MindWalk in a research note on Thursday, April 16th. They issued a “buy” rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

MindWalk Price Performance

The stock has a market cap of $58.62 million, a PE ratio of -6.35 and a beta of 0.65. The company’s 50 day simple moving average is $1.19. The company has a quick ratio of 3.64, a current ratio of 3.74 and a debt-to-equity ratio of 0.21.

MindWalk (NASDAQ:HYFT) last issued its earnings results on Thursday, March 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.50 million. MindWalk had a negative net margin of 66.79% and a negative return on equity of 69.37%. As a group, equities analysts forecast that MindWalk Holdings Corp. will post -0.23 earnings per share for the current fiscal year.

Institutional Trading of MindWalk

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in shares of MindWalk by 8.4% during the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after purchasing an additional 18,600 shares during the period. Jane Street Group LLC raised its stake in shares of MindWalk by 147.3% during the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after purchasing an additional 96,018 shares during the period. XTX Topco Ltd raised its stake in shares of MindWalk by 118.6% during the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after purchasing an additional 44,331 shares during the period. Bank of Montreal Can raised its stake in shares of MindWalk by 81.0% during the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after purchasing an additional 24,500 shares during the period. Finally, Bridgeway Capital Management LLC bought a new stake in shares of MindWalk during the 4th quarter valued at $91,000. 6.70% of the stock is currently owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.